Skip to content

Evolus, Inc.

EOLS· NasdaqCore metricsCIK 1570562

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -3.43%
Market cap
$475.23M
66.19M shares
Filings
558
$77.95M
Q3 2026+11.6% FY25 yoy
-$12.52M
Q3 2026N/M FY25 yoy
-$8.43M
Q3 2026N/M FY25 yoy
-$16.26M
Q3 2026derivedN/M FY25 yoy
-$0.19
Q3 2026N/M FY25 yoy
$41.70M
Q3 2026−38.1% FY25 yoy
$475.23M
—
1.5×
—
-1.03%
—

Twelve months to Sep 30, 2026 · derived

Price

$7.18+3.01%+$0.21past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$297.18MFY 2025
$297.18M0FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$297,176,000reported
FY 20242024-12-31$266,274,000reported
FY 20232023-12-31$202,085,000reported
FY 20222022-12-31$148,616,000reported
FY 20212021-12-31$99,673,000reported
FY 20202020-12-31$56,540,000reported
FY 20192019-12-31$34,925,000reported
FY 20182018-12-31$0reported

Segments

Revenue by Geography, FY2022 to FY2024FY2022United States · FY2022 · $146.15MInternational · FY2022 · $2.47MFY2023United States · FY2023 · $195.42MInternational · FY2023 · $6.66MFY2024United States · FY2024 · $253.16MInternational · FY2024 · $13.12M
LineFY2024ShareChange
United States$253.16M95%+29.5%
International$13.12M4.9%+96.9%
Total$266.27M

From the 10-K filed Mar 4, 2025EOLS

Pharmaceutical preparations

Evolus, Inc. is the 67th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Evolus, Inc. · CIK 1570562 · Engraved from SEC EDGAR